Pinned Tweet
Been here since 2017.
Helped grow projects from 0 → billions MC.
Built communities, wrote Gitbooks, hosted Spaces.
Next chapter: scaling meme culture & communities that stick.
1
5
283
Cryptowaverider retweeted
📢 Immunic will participate in key conferences this June, engaging with the #investor, #industry and #scientific communities.
💼 June 15-16 | H.C. Wainwright Neuro Perspectives Expert Summit (New York & virtual): Erik Lundgren, CEO, and Jason Tardio, President & COO, will participate in a #fireside chat. The presentation will be available via the conference platform and on #Immunic’s IR website.
🌐 June 22-25 | BIO International Convention (San Diego): Members of our management team will participate in #partnering activities.
🔬 June 22-25 | #EFMC-#ACSMEDI Medicinal #Chemistry Frontiers Symposium (Dublin): Dr. Christian Gege, Global Head of #IntellectualProperty, will present work related to #IMU856.
🧠 June 27-30 | European Academy of #Neurology (#EAN) Congress (Geneva): Members of our medical team will be present at #booth E42.
👉 View all details here: bit.ly/4eeu2ve
$IMUX @HCWCO, @IAmBiotech, @EANeurology
@A_Hudson69 look into it brotha, ChatGPT some info on it if you have to.
1
2
38
Cryptowaverider retweeted
Ticker: $IMUX (Immunic Inc.)
Alpha (Bullish Case)
IMUX secured up to $400M in financing, extending runway through 2027 and funding its Phase 3 ENSURE trials in relapsing MS, with top-line data expected by year-end 2026. That removes immediate funding risk and supports its transition toward becoming a commercial-stage biotech.
Technically, price launched from the strong demand zone around $0.50–$0.55 and impulsed into the $1.15–$1.20 supply zone before pulling back toward equilibrium near $0.90. If price holds above that equilibrium area and reclaims $1.00 with strength, a retest of $1.15–$1.20 is likely.
A clean break above supply could open a larger continuation move. Momentum expanded strongly on the breakout, supporting the impulsive structure.
Beta (Risk Case)
This is still a clinical-stage biotech, and valuation ultimately depends on Phase 3 results due late 2026. The sharp rejection from the supply zone suggests near-term exhaustion, and momentum is cooling. If price loses the $0.85–$0.90 equilibrium zone,
downside risk increases toward $0.70–$0.75, with the broader demand zone near $0.55 below that. Failure to hold those levels would suggest this was primarily a news-driven spike rather than the start of a sustained trend.
Cryptowaverider retweeted
🔊 Today, we reported our year-end 2025 #FinancialResults and a #CorporateUpdate. Key highlights include:
🔬 Top-line data from our phase 3 #ENSURE trials in relapsing #MultipleSclerosis (#RMS) expected by year-end 2026
💰 $200 million raised in a private placement, with the potential for up to an additional $200 million
Net proceeds expected to fund:
• Completion of the phase 3 ENSURE trials
• Initiation of a phase 3 trial in primary progressive MS (#PPMS)
• Begin transition into a commercial-stage organization
🚀 With a strengthened financial position and important clinical milestones ahead, we believe 2026 could represent a defining period for the $IMUX team and, specifically, our late-stage MS development pipeline.
👉 Get all the details here: bit.ly/4rEyAR5
#Immunic #FinancialResults #MSResearch #biotech #vidofludimus #IMU838
GM. Wow what a week. A lot of pain has been inflicted. The healing begins. Amazing what I’m seeing across timelines right now. Some thing that make me feel sick. I’ve just been spending time in prayer. This world really needs Jesus.
2
57
The endless battle between Republicans and Democrats is killing this country. They’ll never truly agree, never stop fighting—and in the meantime, people keep dying because of it. #CharlieKirk #america
1
78
Prayer to the family. this sucks! I really can’t believe it.
1
2
83
This one hurts, @charliekirk11 you were a good one brotha.
1
28












